These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1000 related articles for article (PubMed ID: 32613545)

  • 1. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
    Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
    Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
    [No Abstract]   [Full Text] [Related]  

  • 3. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing toxicities of Bruton tyrosine kinase inhibitors.
    Lipsky A; Lamanna N
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):336-345. PubMed ID: 33275698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
    Miao Y; Xu W; Li J
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Bruton's Tyrosine Kinase in CLL.
    Ahn IE; Brown JR
    Front Immunol; 2021; 12():687458. PubMed ID: 34248972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
    Palma M; Mulder TA; Österborg A
    Front Immunol; 2021; 12():686768. PubMed ID: 34276674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
    Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
    J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-generation inhibitors of Bruton tyrosine kinase.
    Wu J; Liu C; Tsui ST; Liu D
    J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Danilov AV; Persky DO
    Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
    Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
    J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Thompson MC; Mato AR
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Javidi-Sharifi N; Brown JR
    Expert Rev Hematol; 2024 Jun; 17(6):201-210. PubMed ID: 38784995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.